Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Novasep Appoints Fine Chemicals Market Director

Published: Thursday, June 06, 2013
Last Updated: Thursday, June 06, 2013
Bookmark and Share
Company strengthens its position by appointing Udo Steinhauer.

Novasep has announced that it has strengthened its position in the fine chemicals marketplace with the appointment of Udo Steinhauer as fine chemicals market director within the synthesis business unit of Novasep.

Udo Steinhauer has a strong industrial experience gained over 18 years in diverse managerial positions.

At Novasep, he will initially focus on four key business areas for Novasep: electronic, cosmetic, flavor and fragrance, and the polymer and biopolymer industry.

“The need for new organic synthesis and purification routes is now critical in the development of the specialty chemicals market,” said Udo Steinhauer.

Steinhauer continued, “As an example, the demand for new organic electronic chemicals in ultrapure quality is continuing to increase. Impurities in cosmetic active ingredients then have to be removed in order to avoid side effects. Another example is in the polymer industry. New additives are required to fulfill the demands of performance plastics and polymers obtained from new synthesis or purification routes of bio-based building blocks. I wanted to join Novasep, with its strong expertise and extended capabilities in organic synthesis and advanced purification, because it is an established player in these markets. It is able to offer a cost-effective response to these increasingly demanding manufacturing challenges.”

“Udo’s appointment is the next significant step in formalizing and developing Novasep’s position in these fine chemical markets,” said Michel Blanc, VP sales and business development of Novasep’s Synthesis Business Unit.

Blanc continued, “These industries require more and more skills in combining smart synthesis with high efficiency purification to develop innovative molecules.”

Novasep offers contract manufacturing solutions using an unparalleled array of specialized techniques that very few companies can handle at one time. This includes hazardous chemistry and large scale chromatography.

The technologies developed by Novasep often allow shorter synthetic pathways and therefore enable significant reduction of costs, time to market and environmental impact.

Novasep’s range of advanced purification techniques include membrane filtration, large scale HPLC, SMB and Varicol® continuous chromatography with integrated solvent recycling capabilities to drastically reduce operating costs.

The main reactions mastered at Novasep at industrial scale include oxidation, azides, nitration, the use of hydrazine, Grignards, alkyllithium, lithium aluminum hydride, carbon disulfide, nitroalkanes and carbonylation reactions.

By outsourcing with Novasep, clients can benefit from Novasep’s 140 years of experience in handling energetic and hazardous chemistry, thereby reducing risk and avoiding CAPEX.

The company offers a full range of integrated services including process development, scale-up and manufacturing from kilogram scale to 1,000’s of tons per year.

In addition to custom manufacturing services, Novasep also provides building blocks, intermediates and specialized reagents.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Opens Indian Subsidiary
New office will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Tuesday, December 10, 2013
Novasep’s European Custom Manufacturing Passes FDA Inspection
Two successful FDA inspections assure customers of Novasep’s strict compliance with US pharmaceutical processing standards.
Thursday, October 24, 2013
Novasep Appoints Christian Thiry as Chief Financial Officer
CFO appointment is a key milestone in Novasep’s senior management recruitment program.
Thursday, August 29, 2013
Novasep Appoints President and CEO
Novasep announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013.
Thursday, June 27, 2013
Novasep Invests to Build World's Largest Chromatography Plant for the Pharmaceutical Industry
The investment of €30 million allows Novasep to build the largest chromatography plant for the production of a large volume commercial API’s in Mourenx, France.
Wednesday, October 10, 2012
Changes to Novasep Governance
Roger-Marc Nicoud becomes non-executive chairman of the board.
Wednesday, October 03, 2012
Novasep Announces Three Million Euro Investment
Company to boost its highly potent API manufacturing capabilities in Le Mans, France.
Friday, July 20, 2012
Novasep Strengthens its Management Team with Key Appointments
Appointment of Jean-Claude Romain as corporate quality director and Alain Lamproye as director of Novasep Bioproduction sites in Belgium.
Tuesday, April 24, 2012
Novasep Opens New Shanghai Facilities
New site increases Novasep’s process development and engineering capabilities to supply turnkey purification processes in East Asia.
Thursday, March 29, 2012
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos